CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer

NCT04560270 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer
Circulating Tumor DNA
KRAS Mutation-Related Tumors

Interventions

DIAGNOSTIC_TEST: Blood samples

Sponsor

Poitiers University Hospital